Advanced cirrhosis is associated with reduced platelet function and altered renal function and sodium handling. Arachidonic acid (AA) metabolites contribute to platelet aggregation and to maintain the response to diuretics in advanced cirrhosis. In the present study, we tested the effects of a dietary supplementation for 8 weeks with a triacylglycerol (triglyceride) enriched in AA (ARASCO ® ; 4 g/day) or oleic acid (OA) on plasma and membrane fatty acid composition, platelet aggregation and renal prostaglandin (PG) metabolism. At baseline, all patients had reduced platelet aggregation. Patients treated with AA showed a significant increase in the percentage of AA in plasma lipids and membrane phospholipids. These changes were associated with an increased platelet aggregation in response to collagen (from 55.83 + − 20.63 to 67.67 + − 14.44 %; P < 0.05). At baseline, all urinary AA metabolites, including PGE 2 , 6-keto-PGF 1α , 8-epi-PGF 2α and 11-dehydro-thromboxane B 2 , were elevated in cirrhotic patients when compared with a group of normal subjects. After furosemide treatment, urinary excretion of 11-dehydro-thromboxane B 2 increased significantly. Supplementation with AA did not result in any significant change in urinary PG excretion either before or after diuretic administration. The results of the present study show that dietary supplementation with AA effectively increases the levels of this fatty acid in plasma and membrane phospholipids and improves platelet aggregation. These data suggest a possible novel approach to the treatment of the haemostatic defect observed in these patients.
INTRODUCTION
The clinical course of advanced cirrhosis is characterized by a number of important complications, including portal hypertension, and its consequences such as gastrooesophageal varices, splenomegaly, ascites and hepatorenal syndrome [1, 2] . Thrombocytopenia and reduced platelet function may contribute to the increased risk of gastrointestinal bleeding observed in these patients [3] . The defect in platelet function is evidenced by the reduced aggregability of platelets in patients with advanced cirrhosis [4, 5] , and several factors are involved in this alteration, including an intrinsic platelet dysfunction [5, 6] . The altered composition of platelet membrane lipids and the reduced synthesis of pro-aggregating thromboxane (TX) A 2 upon stimulation are considered as possible causes of the intrinsic defect [5] [6] [7] [8] . TXA 2 is a metabolite of arachidonic acid (AA; 20:4ω) breakdown and other AA metabolites, including prostaglandins (PGs), are involved in the maintenance of renal perfusion and glomerular filtration rate through a vasodilating effect [9] . In fact, renal PG synthesis, as indicated by urinary PG excretion, is increased in patients with cirrhosis and ascites, whereas it is reduced in cirrhotic patients with functional renal failure [10] [11] [12] .
The liver plays a central role in lipid metabolism and in the synthesis of long-chain polyunsaturated fatty acids, including AA, from 18-carbon precursors. As a consequence of liver disease, the levels of plasma lipids/ lipoproteins as well as the fatty acid profile of plasma and cellular lipids are markedly altered [13] . Membrane alterations include changes in the content of structural lipids, e.g. cholesterol and phosphatidylcholine, in different cell types such as platelets, red blood cells (RBCs) and kidney brush-border membranes [7] [8] [9] [10] [11] [12] [13] [14] . Changes in membrane fatty acids consist of elevation of monounsaturated fatty acids at the expense of saturated fatty acids and AA [7, 8, [14] [15] [16] . AA, a minor component of the normal diet, is mostly synthesized from linoleic acid (18:2ω6) provided by the diet, which is therefore a major determinant in the overall availability of AA. Since the levels of AA in membrane phospholipids affect the tissue production of eicosanoids [17] [18] [19] , a possible strategy to reduce the bleeding tendency and to ameliorate renal function in cirrhotic patients could be aimed at increasing AA content in plasma membrane, platelets and kidney cells. However, we have shown previously [20] that supplementation with linoleic acid and γ -linolenic acid, the initial precursor and an intermediate in AA synthesis respectively, was ineffective in either elevating plasma or membrane AA levels or improving platelet aggregation.
In animal studies, supplementation with AA resulted in increased AA levels in various tissues, such as kidney and circulating cells, and in enhanced generation of AA metabolites [21, 22] . Whelan et al. [22] presented evidence suggesting that low-to-moderate levels of dietary AA have a significant impact on tissue AA content and eicosanoid production. Accordingly, the administration of ethylarachidonate to healthy volunteers increased the amounts of AA in plasma triacylglycerols (triglycerides), phospholipids and cholesteryl esters. Similar changes were found in platelets. AA supplementation resulted in a significant increase in the excretion of 7α-hydroxy-5,11-diketotetranorprostane-1,16-dioic acid, the major urinary metabolite of PGE 2 , and reduced the threshold concentration of ADP necessary to obtain irreversible platelet aggregation [23] .
The recent availability of a triacylglycerol preparation enriched in AA for human studies prompted us to investigate the effects of dietary supplementation with this lipid on plasma fatty acid profiles and platelet function in cirrhotic patients.
METHODS

Subjects
Thirty outpatients with compensated cirrhosis were included in the study. The diagnosis of cirrhosis was established by medical history, clinical examination and laboratory findings and was confirmed by liver biopsy when not contraindicated. Cirrhosis was hepatitis Cvirus-related in 16 patients, hepatitis B-virus-related in three, alcoholic in five, cryptogenic in one and due to autoimmune hepatitis in one patient. All patients had portal hypertension, as indicated by the presence of oesophageal varices at endoscopy, and no ascites, as assessed by physical examination and abdominal ultrasound. No patient had renal failure, hepatocellular carcinoma or other malignancies, recent ( < 6 weeks) gastrointestinal bleeding, hepatic encephalopathy or evidence of intravascular coagulation. The diagnosis of disseminated intravascular coagulation was excluded by repeated platelet count and measurements of fibrinogen levels and D-dimer concentrations in at least two plasma samples.
The investigation conformed to the Declaration of Helsinki, and was approved by the University Ethical Committee. Each patient included in the study gave his/her written informed consent.
Protocol
The study was designed as a randomized double-blind trial. All patients were placed on a standardized, 1800 Kcal diet (where 1 cal ≡ 4.184 J; 55 % carbohydrates, 27 % lipids and 18 % proteins) for 1 week before and throughout the whole study period. On the first day of the study, blood samples and a 24 h urine collection were obtained to evaluate liver and renal function, and to measure plasma cholesterol, triacylglycerols and phospholipids, fatty acid composition of plasma lipids, phospholipids and RBC membranes, platelet aggregation and the urinary excretion rate of PGE 2 , 6-keto-PGF 1α, 8-epi-PGF 2α and 11-dehydro-TXB 2 The following day, after an overnight fast, urine samples were obtained by spontaneous voiding and were discarded. Thereafter, two 1 h urine collections were obtained, before and after intravenous administration of 20 mg of furosemide respectively, for measurements of urinary sodium, PGE 2 , 6-keto-PGF 1α , 8-epi-PGF 2α and 11-dehydro-TXB 2 . Urine samples for measurement of urinary AA metabolites were also obtained in 30 healthy subjects of comparable age and sex.
At the time of enrolment, patients were randomly allocated to receive a daily supplementation of ARASCO ® (4 g/day, n = 15; MARTEK Biosciences Corporation, Columbia, MD, U.S.A.), a triacylglycerol enriched in AA, providing 50 % (w/w) AA, or with a triacylglycerol containing an equivalent amount of oleic acid (OA; n = 15). Both treatments were administered for 8 weeks. At the end of this period, blood and urine (before and after furosemide treatment) were obtained for postsupplementation analysis. Treatments were then stopped, and the same measurements were repeated 4 weeks later.
Lipid extraction
This procedure was carried out according to the method of Folch et al. [24] with chloroform/methanol (2:1, v/v) containing 5 µg/ml of the antioxidant butylated hydroxytoluene as extracting solvents. For RBC membranes, cells were lysed by hypotonic shock and homogenized in an Ultra-Turrax tissue homogenizer in the presence of the extraction solvent and 0.88 % KCl (1:5, v/v). After thorough mixing, the organic and aqueous phases were separated at − 20
• C for at least 2 h. The lipid extracts were evaporated to dryness under a nitrogen stream, and then dissolved in a known volume of chloroform/methanol (2:1, v/v) containing butylated hydroxytoluene.
Separation of lipid classes
Separation of plasma lipid classes (cholesteryl esters, phospholipids, triacylglycerols and non-esterified fatty acids) was carried out by one-dimensional TLC using silica-gel plates (Merck, Darmstadt, Germany) with hexane/ethylic ether/acetic acid (70:30:1, by vol.) as the developing solvent. The identity of each class was confirmed by comparison with the authentic lipid standard (Supelco, Bellefonte, PA, U.S.A.). At the end of the run, phospholipids were visualized by staining with dichloro-fluorescein, scraped off the silica gel and derivatized for fatty acid analysis.
Fatty acid analysis
Analysis of fatty acid methyl esters (FAME) was performed by gas-chromatography, as described elsewhere [20] . FAME were prepared from each lipid class by transesterification with 3M methanolic/HCl (Supelco), and analysed on a capillary gas chromatograph equipped with a flame ionization detector (Perkin-Elmer 8420; Perkin Elmer, Wellesley, MA, U.S.A.), using a cis/trans-FAME column (60 m, internal diameter 0.32 mm, 0.25 µm film; HP-23; Hewlett-Packard, Palo Alto, CA, U.S.A.) and temperature programming (150
• C for 15 min, ramp rate of 2
• C/min, and 220
• C for 20 min). Peaks were identified by comparison with authentic pure reference compounds (Supelco). The percentage distribution of FAME was quantified with a PerkinElmer CC-12 recording integrator. The above method allowed the identification of the following fatty acids: 16:0 (palmitic acid), 16:1 (palmitoleic acid), 18:0 (stearic acid), 18:1 (OA), 18:2ω6 (linoleic acid), 18:3ω6 (linolenic acid), 20:3ω6 (eicosatrienoic acid) and 20:4ω6 (AA).
Preparation of platelet-rich plasma and platelet aggregation
Measurement of aggregation on platelet-rich plasma was carried out as described previously [25] . Platelet-rich plasma was induced to aggregate by collagen (4 µg/ml) at 37
• C in a four-channel aggregometer (Daiichi Kagaku Urinary levels of PGE 2 , PGF 2α and 6-keto-PGF 1α were measured as a reflection of intrarenal PG synthesis by RIA, as described in detail previously [10] . Urinary levels of 8-epi-PGF 2α and 11-dehydro-TXB 2 were measured as a reflection of total body production by RIA validated with different antisera and by comparison with GC/MS, as detailed elsewhere [26, 27] .
Statistical analysis
Comparisons of data between patient groups and between each point of supplementation were carried out with Wilcoxon's signed-rank test. Comparisons of urinary levels of PGF 2α , 8-epi-PGF 2α and 11-dehydro-TXB 2 between patient groups and between each point of supplementation were carried out with ANOVA and Bonferroni t test. Values are expressed as means + − S.E.M; P < 0.05 was considered significant.
RESULTS
Baseline clinical and laboratory data of the 30 patients included in the study are shown in Table 1 . All patients were in Child-Pugh class A [28] , had low platelet counts and showed reduced platelet aggregation in response to collagen, indicating a defective platelet function (Figure 1A) . No differences were observed between the two groups of patients undergoing supplementation with OA or AA. Administration of either AA or OA did not affect any of the laboratory parameters in Table 1 to any appreciable extent. Twenty-three patients (11 in the AA and 12 in the OA group) completed the trial. One patient in the AA withdrew his consent before starting supplementation. Another patient in the AA group and two in the OA group dropped out before completing the supplementation because of gastrointestinal bleeding, refractory ascites and acute pancreatitis respectively. Two patients from the OA group dropped out during the washout period because of gastrointestinal bleeding and portal thrombosis. Finally, one patient from the AA group withdrew his consent during the same period. All adverse events observed during the trial were considered unrelated to supplementation.
Effect of supplementation on fatty acid profile
The fatty acid profiles of plasma lipids and phospholipids and of RBC membrane phospholipids are shown in Table 2 . At the end of the supplementation period with AA (after 8 weeks of treatment), there was a significant increase in AA content of plasma lipids (P < 0.005), phospholipids (P < 0.05) and RBC membrane phospholipids (P < 0.05). At the end of the 4 week washout period (12th week), AA fell to pretreatment values. No changes were observed in the other measured fatty acids in any of the lipid classes evaluated at the end of either the supplementation period or the washout period. No changes in the fatty acid profile were observed in the patients group receiving OA (Table 2) .
Platelet aggregation
At the end of the supplementation period with AA (after 8 weeks of treatment), platelet aggregation in response to collagen significantly increased (P < 0.05) in the AA group, but not in the OA group (Figure 1) . Remarkably, platelet aggregation returned to baseline values at the end of the washout period (12th week), in agreement with changes in AA levels. The AA-treated group also had a trend towards an increased platelet aggregation in response to AA; however, these modifications did not reach statistical significance (Figure 1 ). In baseline conditions, all urinary AA metabolites were significantly elevated in cirrhotic patients when compared with a group of normal healthy subjects (Tables 3 and 4) . After supplementation, no significant differences were observed between the two supplementation groups with respect to sodium excretion or any of the measured urinary AA metabolites ( Table 3) . As expected, furosemide administration was associated with a significant increase in the urinary excretion of sodium and 11-dehydro-TXB 2 in both groups, whereas 8-epi-PGF 2α was not affected by this drug. However, supplementation with either AA or OA had no affect on any of these parameters ( Table 3 ). The results of urinary measurements did not change when expressed as pg/mg of creatinine.
DISCUSSION
Treatments aimed at improving platelet function in cirrhosis are likely to have an impact on the risk of bleeding in these patients. The results of the present study provide evidence that supplementation with a triacylglycerol enriched with AA for 8 weeks effectively increases AA levels in plasma lipids and phospholipids and in membrane phospholipids of cirrhotic patients with defective platelet function. More importantly, a significant increase in platelet aggregation was observed in patients receiving AA, but not in those given OA. It is worth noting that all patients enrolled in the present study had reduced platelet counts and impaired platelet function. The fact that changes in platelet aggregation were related to the supplementation protocol is indirectly confirmed by the observation that this parameter returned to pretreatment levels 4 weeks after withdrawal of AA supplementation. Of note, the improvement in platelet aggregation was less evident when AA was used as an agonist. Although the reasons for these findings are not completely understood, it is likely that high concentrations of AA, such as The finding of an increased AA concentration also in RBC membrane phospholipids indicates stable incorporation of this fatty acid into biological membranes. Although it was not possible to assess the levels of AA in platelet phospholipids due to thrombocytopenia, it is likely that changes in platelet membrane paralleled those observed in RBCs, thus resulting in enhanced TX production [29] .
These observations provide further insight into the pathophysiology of fatty acid metabolism in cirrhosis. In a previous study [20] , dietary supplementation with γ -linolenic acid, the precursor of AA, neither modified plasma and membrane AA levels nor improved platelet aggregation. We considered the possibility that altered intestinal absorption of dietary fatty acids and/or defective incorporation into plasma membranes could explain these negative results. Data from the present study indicate that, if cirrhotic patients are administered Table 3 Urinary excretion rates of 11-dehydro-TXB 2 , 6-keto-PGF 1α , 8-epi-PGF 2α , PGE 2 and PGF 2α before and after furosemide at baseline, at the end of the supplementation period (8th week) and at the end of the washout period (12th week) in cirrhotic patients treated with a triacylglycerol enriched in either OA or AA Values are means + − S.E.M.
* P < 0.05 compared with baseline. §Values for cirrhotic patients at baseline were all significantly different (P < 0.05) compared with normal subjects. DH, dehydro. preformed AA, this fatty acid is effectively absorbed and incorporated into plasma membranes. Therefore the most likely explanation for the lack of effect of AA precursors, such as γ -linolenic acid, is defective desaturation related to an impairment of 5-desaturase activity, as proposed previously [20] . In the present study, supplementation with OA did not modify platelet aggregation, a result at variance with previous data from our group [20] . The most likely explanation for this discrepancy is in the marked difference between the patient populations enrolled in the two studies. In the present study, only patients with compensated class A cirrhosis were enrolled, whereas, in the previous study [20] , 13 out of 15 patients were in more severe functional classes (B and C). This is also reflected by the lower baseline aggregation observed in the previous investigation [20] . Because patients were given a diet containing a large amount of calories and OA, it is likely that a non-specific action of the diet could have accounted for the improvement in platelet aggregation in that study, the effects of which were offset by the generation of increased levels of 20:3ω6 [20] . These effects of the diet were minor in the present study, which included patients with less severe disease and probably better nutritional status [30] . Therefore the lack of changes in platelet aggregation in the OA group provides indirect support to one of the hypotheses formulated in the previous study [20] .
Cirrhotic patients show complex alterations in AA metabolism because, whereas platelet TXA 2 production is decreased, urinary excretion of AA metabolites is increased [5, 10, 11] . This is confirmed by data obtained in the present study, where we observed a significantly higher urinary excretion of TXB 2 and 6-keto-PGF 1α , indexes of renal TXA 2 or PGI 2 generation respectively, as well as of PGF 2α and PGE 2 in cirrhotic patients than in healthy subjects. The increased urinary excretion of AA metabolites indicates an activation of the renal PG system, an event related to the induction of phospholipase A 2 (PLA 2 ) activity within the kidney [31, 32] . The urinary excretion rate of 11-dehydro-TXB 2 was also significantly higher in cirrhotic patients than in control subjects, confirming previous data from our group [33] and other investigators [34] . The mechanisms underlying the increase in 11-dehydro-TXB 2 during cirrhosis are still unclear, although altered hepatic TXA 2 metabolism, increased intrasplenic platelet destruction and in vivo platelet activation may affect TXA 2 entry into systemic circulation [33] .
Furosemide induced a significant increase in urinary 11-dehydro-TXB 2 , thus indicating that the behaviour of this metabolite following loop diuretic administration is comparable with the other PGs. Isoprostanes are a family of PG isomers formed in a free-radical-catalysed manner from a phospholipid-containing AA in situ [35] . These compounds are easily detected in human plasma and urine and their production is markedly enhanced in animal models of free-radical-induced injury. 8-epi-PGF 2α , an F 2 isoprostane, is a potent renal vasoconstrictor and has been shown to exert several biological activities in vivo and in vitro [35] . Few studies have investigated the levels and possible role of isoprostanes in cirrhotic patients. Plasma F 2 isoprostane levels have been found to be markedly elevated in patients with the hepatorenal syndrome, whereas normal levels were reported in cirrhotic patients without renal dysfunction [36] . Another group [37] reported that the urinary excretion of 8-epi-PGF 2α is higher in patients with more advanced disease and that the increased 8-epi-PGF 2α excretion probably reflects an increased formation rather than a decreased clearance. Data obtained in the present study show that an increased production of 8-epi-PGF 2α also occurs in patients with compensated cirrhosis and maintained renal function, such as those included in our study. Moreover, the renal metabolism of 8-epi-PGF 2α , at variance with other PGs, is not furosemide related.
Several AA metabolites are critical for the maintenance of renal function in advanced cirrhosis, as suggested by the marked impairment in renal function and the response to loop diuretics after administration of nonsteroidal anti-inflammatory drugs [9] . We tested whether supplementation with AA was able to modify the urinary excretion of AA metabolites or to increase the natriuretic response to furosemide in cirrhotic patients. However, no significant changes were observed either in the urinary levels of AA metabolites or in the diuretic and natriuretic response to furosemide. Although the reasons for this lack of effect are unclear, different explanations can be proposed. Patients included in the present study had an increased urinary excretion of PGs and it could be difficult to observe a further increase in PG synthesis in the context of an activated system. On the other hand, the possibility cannot be ruled out that the duration of supplementation was too short to affect the membranes of cells with a slow turnover, such as renal tubular cells. Finally, it is possible that the renal compartment is less accessible than circulating cells to the exchanges of lipids with plasma lipoproteins. Although these hypotheses are not mutually exclusive, further investigation is needed to better define this aspect.
In conclusion, in a double-blind placebo-controlled trial, supplementation with a triacylglycerol enriched in AA increased the AA levels in plasma and membrane lipids in a group of cirrhotic patients with defective platelet aggregation and improved the aggregating response. These results suggest a possible novel approach to the treatment of the haemostatic defect observed in these patients.
